Pasithea Therapeutics Corp.

NasdaqCM KTTA

Pasithea Therapeutics Corp. Price to Sales Ratio (P/S) on January 14, 2025: 3.28

Pasithea Therapeutics Corp. Price to Sales Ratio (P/S) is 3.28 on January 14, 2025, a -65.09% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Pasithea Therapeutics Corp. 52-week high Price to Sales Ratio (P/S) is 11.32 on April 04, 2024, which is 245.68% above the current Price to Sales Ratio (P/S).
Pasithea Therapeutics Corp. 52-week low Price to Sales Ratio (P/S) is 3.28 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
Pasithea Therapeutics Corp. average Price to Sales Ratio (P/S) for the last 52 weeks is 6.88.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: KTTA

Pasithea Therapeutics Corp.

CEO	Dr. Tiago Reis Marques M.D., Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	1111 Lincoln Road
Employees	8
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Key trends

Past 5 years